Heron Therapeutics is trading at $0.35, up +5.39%, with the gain appearing to reflect low-priced-stock volatility and momentum after the prior session’s +5.47% move.
- No fresh company-specific announcement or major catalyst was identified for September 4, 2026.
- Recent coverage remains focused on August 10 results, withdrawn guidance, CINVANTI patent uncertainty, and strategic alternatives.
- Broader markets are mixed, offering limited evidence of a market-wide trigger; the move appears unrelated to a confirmed new development.